Search the GHTC website

Global health R&D delivers for Maryland

US government investment in global health R&D has delivered

Amount
$8.7 billion
to Maryland research institutions
Jobs
105,600+ new jobs
for Maryland
Maryland's top USG-funded global health R&D institutions

Maryland's top USG-funded global health R&D institutions

Johns Hopkins University (including the Bloomberg School of Public Health)
$819.1 million
Leidos Biomedical Research
$813.9 million
University of Maryland, Baltimore (including Center for Vaccine Development and Global Health)
$326.2 million
Advanced Bioscience Laboratory
$315.6 million
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
$313.8 million
US Army Fort Detrick (self-funding or other agency transfers)
$192.1 million
Technical Resources International Inc. (TRI)
$166.7 million
Westat Inc.
$125.6 million
Sanaria Inc.
$123.4 million
International Partnership for Microbicides*
$103 million
Social & Scientific Systems Inc.*
$92.7 million
Profectus Biosciences Inc.*
$56.5 million
Abviro LLC
$36.9 million
Quality Biological Inc.
$36 million
University of Maryland, College Park
$32.1 million
BIOQUAL
$31.5 million
Akonni Biosystems Inc.
$29.1 million
Imquest BioSciences
$24.7 million
Biomedical Research Institute
$24.1 million
Ellume
$23.2 million
Unither Virology
$22.1 million
EMMES Corporation
$20 million
Integrated BioTherapeutics Inc.
$19.4 million
Emergent Biosolutions
$16 million
Foundation for the National Institutes of Health
$11.3 million
Axle Informatics
$10.1 million
Zalgen Labs
$9.3 million
US Uniformed Services University of the Health Sciences (self-funding or other agency transfers)
$9.1 million
Medical Science & Computing LLC (MSC)
$8.9 million
DynPort Vaccine Company
$8.7 million
Sequella
$7.4 million
Protein Potential
$6.4 million
Accelevir Diagnostics LLC
$5.8 million
Digital Infuzion
$5.8 million
Intralytix
$4.9 million
Gryphon Scientific
$4.6 million
MacroGenics
$4.5 million
Radix Pharmaceuticals Inc.*
$4.5 million
Scanogen
$3.8 million
Undisclosed MD-based industry recipient
$3.5 million
US Food and Drug Administration (self-funding or other agency transfers)
$3.4 million
Aeras*
$3.1 million
Plantvax
$3 million
VLP Therapeutics
$2.9 million
Novel Microdevices Inc. (formerly Novel Dx)
$2.8 million
Tengen Biomedical
$2.8 million
PathoVax
$2.7 million
University of Maryland Biotechnology Institute*
$2.3 million
GenVec*
$2 million
Meso Scale Diagnostics LLC
$1.7 million
Precision Bioservices
$1.2 million
US Health Resources & Services Administration (self-funding or other agency transfers)
$1.1 million
DFH Pharma
$1 million
Codex Biosolutions Inc.
$965 thousand
Rakta Therapeutics
$862 thousand
Definitive Biotechnologies LLC
$810 thousand
Lieber Institute for Brain Development
$758 thousand
EMINENT Services Corporation
$739 thousand
Information Management Services Inc. (IMS)
$721 thousand
Biofactura Inc.
$719 thousand
Imec Group LLC
$687 thousand
ReProtect*
$682 thousand
Cascade Therapeutics
$539 thousand
Sigmovir Biosystems
$539 thousand
Lumina Corps (formerly NOVA Research Company)
$536 thousand
Towson University
$506 thousand
LTS Corporation*
$469 thousand
Bacilligen Inc.*
$341 thousand
Council Rock Consulting
$338 thousand
SD Nanosciences*
$313 thousand
Infratrac Inc.
$304 thousand
Rise Therapeutics
$283 thousand
CosmosID Inc.
$278 thousand
Medigen Inc.
$266 thousand
Prompt Diagnostics LLC
$259 thousand
Kennedy Krieger Institute (including Hugo W. Moser Research Institute)
$234 thousand
CAMRIS International
$216 thousand
Zeteo Tech
$167 thousand
Celadon Laboratories Inc.*
$141 thousand
TA Management Solutions
$133 thousand
Parklawn North Lot LLC
$125 thousand
Tetracore
$105 thousand
Tilt-Up Construction Inc.
$91 thousand
MedStar Health Research Institute
$85 thousand
FCN Inc.
$73 thousand
Advanced Automation Technologies
$69 thousand
Ripple Effect Communications Inc.
$62 thousand
Hememics Biotechnologies Inc.
$28 thousand
Communications Electronics Inc.
$21 thousand
Global Solutions Network Inc.
$20 thousand
US National Institutes of Health (self-funding or other agency transfers)
$4.8 billion

Maryland's top areas of global health R&D by USG funding

12.2%
COVID-19
2.2%
Diarrheal diseases
5.9%
Flioviral diseases (including Ebola, Marburg)
47%
HIV/AIDS
12%
Malaria
4.4%
Neglected tropical diseases
Buruli ulcer
Dengue
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Leprosy
Trachoma
5.9%
Tuberculosis
10.3%
Other
Arenaviral hemorrhagic fevers (including Lassa fever)
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Chikungunya
Cryptococcal meningitis
Emergent non-polio enteroviruses (including EV71, D68)
Henipaviral diseases (including Nipah)
Hepatitis B
Hepatitis C
Histoplasmosis
Mpox
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Reproductive health
Salmonella infections
Zika
Global health R&D at work in Maryland

University of Maryland’s Center for Vaccine Development and Global Health is at the forefront of advancing next-generation vaccines for malaria. The center led clinical trials of a promised whole parasite vaccine candidate developed by the Maryland-based biotech Sanaria. It is also conducting the first-in-human studies of an mRNA-based malaria vaccine developed by BioNTech—the maker of the Pfizer/BioNTech COVID-19 vaccine—which also runs a facility in the state of Maryland. Vaccines are an important tool in the ongoing fight against malaria. While vaccines for this age-old disease have recently become available, next-generation versions are needed that have fewer doses and improved efficacy.

Footnotes
  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: Maryland GovPics/JayBaker